Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

WASHINGTON (AP) — Drugmaker Sarepta Therapeutics (SRPT) said precocious Friday it won't comply with a petition from the Food and Drug Administration to halt each shipments of its cistron therapy pursuing the decease of a 3rd patient receiving 1 of its treatments for muscular dystrophy.

The highly antithetic determination is simply a latest successful a drawstring of events that person hammered the company's banal for weeks and precocious forced it to laic disconnected 500 employees. The company's determination not to comply with the FDA besides places aboriginal availability of its starring therapy, called Elevidys, successful doubt.

The FDA said successful a connection Friday nighttime that officials met with Sarepta and requested it suspend each income but “the institution refused to bash so.” The bureau has the authorization to propulsion drugs from the market, but the cumbersome regulatory process tin instrumentality months oregon adjacent years. Instead, the bureau usually makes an informal petition and companies astir ever comply.

“We judge successful entree to drugs for unmet aesculapian needs but are not acrophobic to instrumentality contiguous enactment erstwhile a superior information awesome emerges,” FDA Commissioner Marty Makary said successful a statement.

Elevidys is the archetypal cistron therapy approved successful the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting illness that affects males, though it has faced scrutiny since its clearance successful 2023. The one-time attraction received accelerated support against the recommendations of immoderate FDA scientists who doubted its effectiveness.

The FDA granted afloat support past twelvemonth and expanded the therapy’s usage to patients 4 years and older, including those who tin nary longer walk. Previously, it was lone disposable for younger patients who were inactive walking.

Sarepta said Friday that its technological reappraisal showed “no caller oregon changed information signals” for younger patients with Duchenne’s who person earlier stages of the disease. The institution said it plans to support the cause disposable for those patients.

“We look guardant to continued discussions and sharing of accusation with FDA,” the institution said successful a statement.

Sarepta halted shipments past period of the therapy for older boys with Duchenne’s, which gradually destroys musculus and skeletal strength, resulting successful aboriginal death. The determination followed the deaths of 2 teenage boys taking the therapy.

The institution besides confirmed a 3rd decease Friday: a 51-year-old diligent who was taking an experimental cistron therapy successful a proceedings for a antithetic signifier of muscular dystrophy. Sarepta said it reported the decease to the FDA connected June 20. The FDA said Friday it placed that proceedings connected hold.

Sarepta noted that the cistron therapy progressive successful the incidental uses “a antithetic dose and is manufactured utilizing a antithetic process,” than Elevidys.